Characteristics and Outcomes of Eosinophilic Fasciitis-Associated Monoclonal Gammopathy

Daniel R Mazori; Bina Kassamali; Michelle S Min; Morgan Schaefer; Avery H LaChance; Adam S Sperling; Ruth Ann Vleugels

doi:10.1001/jamadermatol.2021.4302

Characteristics and Outcomes of Eosinophilic Fasciitis-Associated Monoclonal Gammopathy

JAMA Dermatol. 2021 Dec 1;157(12):1508-1509. doi: 10.1001/jamadermatol.2021.4302.

Authors

Daniel R Mazori^{1

2

3}, Bina Kassamali^{1

2}, Michelle S Min^{1

2

4}, Morgan Schaefer¹, Avery H LaChance^{1

2}, Adam S Sperling^{2

5

6}, Ruth Ann Vleugels^{1

2}

Affiliations

¹ Department of Dermatology, Brigham and Women's Hospital, Boston, Massachusetts.
² Harvard Medical School, Boston, Massachusetts.
³ The Ronald O. Perelman Department of Dermatology, NYU Grossman School of Medicine, New York, New York.
⁴ Department of Dermatology, University of California Irvine School of Medicine, Irvine.
⁵ Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts.
⁶ Division of Hematology, Brigham and Women's Hospital, Boston, Massachusetts.

Abstract

This cross-sectional study analyzes the characteristics and outcomes of eosinophilic fasciitis–associated monoclonal gammopathy.

Publication types

Letter
Research Support, N.I.H., Extramural

MeSH terms

Cross-Sectional Studies
Eosinophilia* / complications
Eosinophilia* / diagnosis
Fasciitis* / diagnosis
Humans
Paraproteinemias* / complications
Paraproteinemias* / diagnosis

Supplementary concepts

Eosinophilic Fasciitis

Grants and funding

K08 CA252174/CA/NCI NIH HHS/United States